A passionate team and partners
How to Navigate the Website
What people say about us
Uncomplicating HD Research: Mission Accomplished
– November 28th, 2022
On November 12th, in close collaboration with AVAEH – Asociación Valenciana de Enfermedad de Huntington and the Instituto de Investigación Sanitaria La Fe we were able to bring together a fantastic group of Spanish clinicians and researchers who are completely committed to providing the best care possible to HD families and to finding effective therapeutic options for those impacted by HD.
Bookshelf - Open Books, Open Minds!
– November 10th, 2022
The Moving Forward team is happy to announce a new feature in the Moving Forward webpage, the Bookshelf. The team has compiled many interesting books of different genres, all of them related to Huntington’s Disease (HD). Here you can find a comprehensive list with a summary of each book and additional information about where to buy or read it online 📖
🎯 Since one of the main goals of Moving Forward is to increase the health literacy and provide reliable information to the HD community, the project team thought it would be interesting to have a new section dedicated to all you book lovers out there.
Moving Forward Poster Trilogy at the EHDN2022 Bologna Meeting
– October 18th, 2022
Filipa Júlio, the Moving Forward Project Manager, and Ruth Blanco, the Moving Forward Project Coordinator in Spain, attended the EHDN Plenary Meeting in Bologna last month. This was the first opportunity to present in-person the Moving Forward (MF) work to more than 1000 participants from all over the world who attended the largest and more important international HD conference.
Prilenia Phase 3 Trial with Pridopidine – Why is it Different?
– September 13th, 2022
For all those who have been following Huntington’s disease research for some time, Pridopidine is an “old acquaintance”.
To date, several studies have been conducted with this drug, looking closely to its effect on dopamine. Although they have helped us to confirm the safety and good tolerability of pridopidine, none of these trials has been completely successful.
UniQure: the Highs and Lows of AMT-130
– September 9th, 2022
UniQure is a company with an expertise in gene therapy that has long been involved in the search for HD treatment options. Their preclinical studies in animal models showed that AMT-130, the gene therapy product candidate for HD, reduced the mutant huntingtin protein and was associated with a decrease in the progression of Huntington’s disease signs.
PIVOT-HD, PTC Therapeutics Phase 2 Trial to Lower Huntingtin
– September 8th, 2022
PTC Therapeutics is a US biopharmaceutical company specialized in the development of gene therapies for rare diseases. The team at PTC Therapeutics has screened more than 300,000 molecules in the search for an effective therapeutical approach to HD, one that can lower huntingtin, can be administered orally and can have an impact inside and outside of the brain.